Adaptive Biotechnologies' MRD growth and profitability shine, yet long-term risks call for caution. Click here to find out ...

Analysts' ratings for Adaptive Biotechnologies (NASDAQ:ADPT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below ...

Adaptive Biotechnologies' MRD segment continues to show strong growth, with a 36% increase in revenue and clonoSEQ test volumes. The immune medicine segment remains weak, with a 66% drop in revenue, ...

Fintel reports that on September 30, 2025, Guggenheim initiated coverage of Adaptive Biotechnologies (NasdaqGS:ADPT) with a ...

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

In the past week, Adaptive Biotechnologies received an improved earnings outlook from analysts, with the consensus full-year earnings estimate rising by 17.6% in the most recent quarter and the ...

Adaptive Biotechnologies reported a 42% revenue increase in its MRD segment, with a focus on achieving profitability in 2025. Adaptive Biotechnologies Corporation reported its financial results for ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.0, a high estimate of $20.00, and a low estimate of $14.00. Observing a 33.33% increase, the current ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The market continued its ...

SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...